Table 1 Baseline characteristics of all RA patients and of subgroups of ACPA-positive and ACPA-negative patients
All RA patients (n = 299) | ACPA-positive RA patients (n = 158) | ACPA-negative RA patients (n = 141) | |
|---|---|---|---|
Age in years, mean (SD) | 57 (14) | 54 (14) | 60 (14) |
Female, n (%) | 198 (66) | 105 (66) | 93 (66) |
Symptom duration in weeks, median (IQR) | 15 (8–32) | 18 (9–38) | 12 (5–26) |
(Sub)acute symptom onset, n (%) | 95 (34) | 39 (27) | 56 (43) |
66-SJC, median (IQR) | 6 (3–11) | 5 (2–8) | 8 (3–12) |
68-TJC, median (IQR) | 9 (4–15) | 7 (4–13) | 10 (4–18) |
RF positivity, n (%) | 183 (61) | 134 (85) | 49 (35) |
ESR (mm/h), median (IQR) | 28 (14–41) | 28 (14–41) | 28 (11–41) |
CRP (μg/mL), median (IQR) | 10 (3–23) | 8 (3–18) | 12 (3–30) |
PTGA (0–100), median (IQR) | 70 (50–80) | 70 (45–80) | 70 (60–80) |
DAS44, median (IQR) | 2.9 (2.4–3.4) | 2.8 (2.3–3.3) | 3.0 (2.5–3.7) |
MBDA category | |||
Low (< 30), n (%) | 43 (14) | 26 (16) | 17 (12) |
Moderate (30–44), n (%) | 64 (21) | 35 (22) | 29 (21) |
High (> 44), n (%) | 192 (64) | 97 (61) | 95 (67) |